58 related articles for article (PubMed ID: 38668776)
1. Nanoparticle Polymeric Micellar Paclitaxel Versus Paclitaxel for Patients with Advanced Gastric Cancer.
Wang FY; Huang XM; Cao YQ; Cao J; Ni J; Li K; Lu M; Huang XE
J Gastrointest Cancer; 2024 Apr; ():. PubMed ID: 38668776
[TBL] [Abstract][Full Text] [Related]
2. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial.
Shi M; Gu A; Tu H; Huang C; Wang H; Yu Z; Wang X; Cao L; Shu Y; Wang H; Yang R; Li X; Chang J; Hu Y; Shen P; Hu Y; Guo Z; Tao M; Zhang Y; Liu X; Sun Q; Zhang X; Jiang Z; Zhao J; Chen F; Yu H; Zhang W; Sun J; Li D; Zhou J; Han B; Wu YL
Ann Oncol; 2021 Jan; 32(1):85-96. PubMed ID: 33130217
[TBL] [Abstract][Full Text] [Related]
3. [Preliminary report of semimonthly 5-fluorouracil/leucovorin combined with paclitaxel in treatment of advanced gastric cancer (AGC)].
Zhou NN; Zhou ZM; Liu MZ; Li YH; Xu RH; Teng XY; Xiang XJ; Tian WH; Liu DG; Hu PL; Zhang B; Qiu HJ; Qian SY; He YJ
Ai Zheng; 2003 Aug; 22(8):867-9. PubMed ID: 12917037
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of albumin-bound paclitaxel in advanced gastric cancer patients].
Gong JF; Lu M; Li J; Li Y; Zhou J; Lu ZH; Wang XC; Li J; Zhang XT; Shen L
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Feb; 46(1):144-8. PubMed ID: 24535367
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies.
Shi M; Sun J; Zhou J; Yu H; Yu S; Xia G; Wang L; Teng Y; Liu G; Yu C; Feng J; Shen Y
Invest New Drugs; 2018 Apr; 36(2):269-277. PubMed ID: 28868573
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
7. Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy.
Roviello G; Martina C; Winchler C; De Gennaro Aquino I; Papa F; Buttitta E; Rossi G; Antonuzzo L
J Gastrointest Cancer; 2023 Sep; 54(3):802-808. PubMed ID: 36109437
[TBL] [Abstract][Full Text] [Related]
8. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Lordick F; Carneiro F; Cascinu S; Fleitas T; Haustermans K; Piessen G; Vogel A; Smyth EC;
Ann Oncol; 2022 Oct; 33(10):1005-1020. PubMed ID: 35914639
[No Abstract] [Full Text] [Related]
9. Polymeric micellar paclitaxel (Pm-Pac) prolonged overall survival for NSCLC patients without pleural metastasis.
Lu J; Gu A; Wang W; Huang A; Han B; Zhong H
Int J Pharm; 2022 Jul; 623():121961. PubMed ID: 35764263
[TBL] [Abstract][Full Text] [Related]
10. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in nanomedicine for enhanced cancer chemotherapy.
Wei G; Wang Y; Yang G; Wang Y; Ju R
Theranostics; 2021; 11(13):6370-6392. PubMed ID: 33995663
[TBL] [Abstract][Full Text] [Related]
12. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
13. Clinical applications of nanomedicines in lung cancer treatment.
Norouzi M; Hardy P
Acta Biomater; 2021 Feb; 121():134-142. PubMed ID: 33301981
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
